Novartis AG (NVS) Stock: Price, Forecast & Analyst Target
Novartis AG (NVS) — MoonshotScore 86/100 (Exceptional band), calculated Oct 26, 2026. Price $153.60 (+1.64%), as of the Oct 26, 2026 trading session; market cap $292B. Expected results Oct 27, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 37.97× (market value Oct 26, 2026; cash Jun 30, 2026) · expected results Oct 27, 2026
Novartis AG · NVS · NYSE · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Novartis develops, manufactures and markets prescription medicines, with emphasis on oncology, immunology, neuroscience and cardiovascular disease rather than earning fees for delivering care. Durable value creation requires its leading medicines to keep expanding while research spending replenishes a sales base concentrated in major products.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Novartis AG (NVS)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $14.42B (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 6 of 8
- Altman Z 3.48 · Piotroski F 6
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 86 | Exceptional | |
| 87 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional |
The score was 86 in the stored Oct 24, 2026 snapshot and remains 86 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Valuation +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $153.60 | |
| Change on the day | +1.64% | |
| 52-week range | $121.57 – $170.46 | |
| Market capitalisation | $292B | |
| Price / earnings (trailing) | 23.48 | |
| Shares traded on the day | 1.72M | |
| Beta (volatility vs the S&P 500) | 0.42 | |
| Dividends per share (last 12 months) | $4.74 | |
| Dividend yield (last 12 months) | 3.14% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for Novartis AG (NVS): Bullish Lean
74/100 · ASome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 26, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the NVS film — every key number, told as a short cinematic story
~2 min · open the film
What is Novartis AG (NVS), and what does it report?
Short answer · as of
The Swiss parent is a holding company, but its operating engine is the sale of innovative prescription medicines and established brands.
Research dated 2026-09-12.
The Swiss parent is a holding company, but its operating engine is the sale of innovative prescription medicines and established brands. Reported revenue therefore measures consolidated product sales, not patient visits, insurance premiums or service fees.
The portfolio spans several therapeutic areas, yet the disclosed segment view shows substantial concentration in leading products. Quarterly results compress those product economics into revenue, gross profit, research expense, commercial and administrative expense, operating profit and net income.
What do the latest results show for Novartis AG (NVS)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $14.42B.
Research dated 2026-09-12.
The latest period reversed the preceding revenue dip: revenue, gross profit, operating profit, net income and diluted earnings all improved sequentially. Against the comparable earlier period, however, revenue and profit remained lower, making the move a rebound rather than a complete recovery.
Additional gross profit more than absorbed higher research and commercial spending, while operating cash flow strengthened and capital expenditure eased. The latest earnings release also exceeded both revenue and earnings expectations after the preceding release fell short on both measures.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $14.42B Jun 30, 2026
- Latest quarter · R&D
- $2.76B Jun 30, 2026
- Latest quarter · SG&A
- $3.24B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $4.74B Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $14.42B | $2.76B | $3.24B | $4.74B |
| Mar 31, 2026 | $13.52B | $2.74B | $3.14B | $4.24B |
| Dec 31, 2025 | $13.33B | $2.84B | $3.44B | $3.52B |
| Sep 29, 2025 | $14.36B | $2.94B | $3.31B | $4.50B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $14.41B Jul 21, 2026
- Latest report · revenue estimate
- $14.07B Jul 21, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 21, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 21, 2026 | $14.41B | $14.07B | $2.4100 | $2.1700 |
| Apr 28, 2026 | $13.11B | $13.44B | $1.9900 | $2.1100 |
| Feb 4, 2026 | $13.34B | $13.70B | $2.0300 | $1.9900 |
| Oct 28, 2025 | $14.36B | $13.64B | $2.2500 | $2.2600 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $14.42B | $3.27B | $1.71 (diluted) |
| Q1 FY2026 | $13.52B | $3.16B | $1.65 (diluted) |
| Q4 FY2025 | $13.33B | $2.41B | $1.25 (diluted) |
| Q3 FY2025 | $14.36B | $3.93B | $2.02 (diluted) |
What are the financial strengths and risks for Novartis AG (NVS)?
Short answer
Cash and short-term investments were $7.69B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $5.89B for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Novartis produces substantial operating cash and carries modest capital expenditure relative to that inflow, giving the commercial portfolio capacity to fund research internally. Profitability is also supported by strong gross and operating margins.
The balance sheet is not built around net cash: debt greatly exceeds cash and investments, while near-term liquidity ratios remain below parity. Cash and short-term investments have declined materially across the reported window despite their latest sequential increase.
Product concentration connects the financial and operating risks. Weakening demand for leading medicines could pressure revenue and cash generation before research spending yields enough commercial replacement.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $5.89B Jun 30, 2026
- Previous quarter · operating cash flow
- $3.68B Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $5.89B | −$321.07M |
| Mar 31, 2026 | $3.68B | −$807.00M |
| Dec 31, 2025 | $2.25B | −$610.90M |
| Sep 29, 2025 | $6.57B | −$831.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Novartis AG (NVS)?
Short answer · as of
The next earnings report is expected on Oct 27, 2026.
Research dated 2026-09-12.
The approaching earnings release should be read for persistence: whether prescription-medicine revenue continues its sequential recovery, whether gross profit again converts into stronger operating income, and whether cash generation remains robust after lighter capital spending.
Consensus projections assume continued revenue and earnings expansion across the forecast horizon. Recent estimate outcomes have been uneven, so repeated delivery matters more than an isolated beat; cash should also be watched because strong operating inflows have coexisted with a lower balance over the broader window.
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Novartis AG compare with its peers?
Short answer
Novartis AG's score ranks tied for 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Novartis resembles a mature global pharmaceutical manufacturer more than a development-stage biotechnology company: marketed medicines already generate sizable profit and cash flow that can finance a broad research program.
Its diversification comes from therapeutic areas and specialized therapies, not from unrelated healthcare service lines. That breadth still leaves meaningful product concentration, because leading medicines historically supplied most of the disclosed portfolio revenue; compared with a net-cash biotechnology business, Novartis also carries a materially different debt profile.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1279.14 Oct 26, 2026 | $1.20T | 98 5-pillar Oct 26, 2026 | |
| $61.28 Oct 26, 2026 | $125B | 92 5-pillar Oct 26, 2026 | |
| $266.30 Oct 26, 2026 | $641B | 90 5-pillar Oct 26, 2026 | |
| $50.75 Oct 23, 2026 | $102B | 89 5-pillar Oct 26, 2026 | |
| $172.06 Oct 26, 2026 | $267B | 88 5-pillar Oct 26, 2026 | |
| $444.63 Oct 26, 2026 | $240B | 87 5-pillar Oct 26, 2026 | |
| Novartis AG (NVS) — this page | $153.60 | $292B | 86 |
| $41.65 Oct 26, 2026 | $99.9B | 86 5-pillar Oct 26, 2026 | |
| $285.64 Oct 23, 2026 | $505B | 80 5-pillar Oct 26, 2026 | |
| $145.27 Oct 23, 2026 | $358B | 76 5-pillar Oct 26, 2026 | |
| $250.69 Oct 23, 2026 | $37.0B | 70 5-pillar Oct 26, 2026 | |
| $30.03 Oct 23, 2026 | $171B | 69 5-pillar Oct 26, 2026 | |
| $156.04 Oct 23, 2026 | $193B | 67 5-pillar Oct 26, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $136.00 – $156.00
- Consensus target
- $146.00
- Median target
- $146.00
Consensus record · Captured .
Measured against a quoted price of $153.60 (as of Oct 26, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 7.1% Period end Jun 30, 2026
- Previous quarter · ownership
- 7.6% Prior to period end Jun 30, 2026
- Reporting holders
- 1,675 Period end Jun 30, 2026
- Previous quarter · holders
- 1,641 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fisher Asset Management, LLC | 15,523,378 |
| Morgan Stanley | 8,726,827 |
| Dimensional Fund Advisors LP | 8,117,586 |
| Primecap Management Co/Ca/ | 6,592,124 |
| Loomis Sayles & Co L P | 5,239,309 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What Investors Ask About Novartis AG (NVS) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What does Novartis actually sell in oncology, immunology and neuroscience?
Novartis sells prescription medicines across those therapeutic areas, alongside cardiovascular treatments, established brands and other specialized therapies. Its revenue is product revenue rather than payment for delivering clinical care.
Did the latest Novartis earnings release restore the prior profit level?
Results improved sharply from the preceding period, but revenue, operating profit, net income and diluted earnings remained below the comparable earlier period. The latest release nevertheless surpassed both revenue and earnings expectations.
Can Novartis fund research from its medicine portfolio?
Operating cash flow comfortably exceeded capital expenditure in the reported periods, while the income statement shows sustained heavy research spending. The commercial portfolio is therefore generating internal funding for continued development work.
Why do Novartis leading medicines matter so much to financial risk?
Leading products historically contributed most of the disclosed portfolio revenue. Demand weakness among those medicines could affect consolidated sales faster than breadth across therapeutic areas might suggest.
What is the NVS stock price today?
The last price recorded on this page for Novartis AG (NVS) is $153.60, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the NVS price target?
The analyst consensus price target for Novartis AG (NVS) is $146.00 (range $136.00 to $156.00, median $146.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does NVS pay a dividend?
Yes. Novartis AG (NVS) shows a trailing 12-month dividend yield of 3.14%, as of Oct 23, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (83 figures)
The 83 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Lichtstrasse 35, Basel, V8, CH 4056 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Lichtstrasse 35, Basel, BS, 4056, CH". |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 27, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $153.60 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T17:24:49.547Z. | |
px.change | Change on the day | +1.64% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $292B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T17:24:46.000Z. Captured from FMP at 2026-10-26T17:24:48.321Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$2.48 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $14.42B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | 23.48 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.72M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.42 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Vasant Narasimhan | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 75,267 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $43.97B, net result $24.02B; FY2022 revenue $43.46B, net result $6.96B; FY2023 revenue $46.66B, net result $14.85B; FY2024 revenue $51.72B, net result $11.94B; FY2025 revenue $54.81B, net result $14.06B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Top 20 products $32.14B · Rest of portfolio $9.16B · Total anti-infectives net sales $1.20B · Anti Infectives sold under Sandoz name $777.00M | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 74.3% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $14.42B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $2.76B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $3.24B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $4.74B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $13.52B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $2.74B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $3.14B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $4.24B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $13.33B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $2.84B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $3.44B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $3.52B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-29.revenue_k | Revenue — period end 2025-09-29 | $14.36B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-29.rd_k | R&D — period end 2025-09-29 | $2.94B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-29.sga_k | SG&A — period end 2025-09-29 | $3.31B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-29.operating_result_k | FMP standardized operating result — period end 2025-09-29 | $4.50B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-21.revenue_actual | Revenue · reported — report date 2026-07-21 | $14.41B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.revenue_estimated | Revenue · estimate — report date 2026-07-21 | $14.07B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.eps_actual | EPS · reported — report date 2026-07-21 | $2.4100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-21.eps_estimated | EPS · estimate — report date 2026-07-21 | $2.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.revenue_actual | Revenue · reported — report date 2026-04-28 | $13.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.revenue_estimated | Revenue · estimate — report date 2026-04-28 | $13.44B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.eps_actual | EPS · reported — report date 2026-04-28 | $1.9900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-28.eps_estimated | EPS · estimate — report date 2026-04-28 | $2.1100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.revenue_actual | Revenue · reported — report date 2026-02-04 | $13.34B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.revenue_estimated | Revenue · estimate — report date 2026-02-04 | $13.70B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.eps_actual | EPS · reported — report date 2026-02-04 | $2.0300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-04.eps_estimated | EPS · estimate — report date 2026-02-04 | $1.9900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_actual | Revenue · reported — report date 2025-10-28 | $14.36B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.revenue_estimated | Revenue · estimate — report date 2025-10-28 | $13.64B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_actual | EPS · reported — report date 2025-10-28 | $2.2500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-28.eps_estimated | EPS · estimate — report date 2025-10-28 | $2.2600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $7.69B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $5.89B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $2.37B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $49.01B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 7.10× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $5.89B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $3.68B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$321.07M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$807.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $2.25B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$610.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-29.operating_cash_flow_m | Operating cash flow — period end 2025-09-29 | $6.57B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-29.capex_m | Capital expenditure (reported) — period end 2025-09-29 | −$831.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $136.00 – $156.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $146.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $146.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 7.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 7.6% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 1,675 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 1,641 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fisher Asset Management, LLC — shares in provider snapshot | 15,523,378 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Morgan Stanley — shares in provider snapshot | 8,726,827 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Dimensional Fund Advisors LP — shares in provider snapshot | 8,117,586 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Primecap Management Co/Ca/ — shares in provider snapshot | 6,592,124 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Loomis Sayles & Co L P — shares in provider snapshot | 5,239,309 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-25 | |
fin.scores | Distress and quality screens | Altman Z 3.48 · Piotroski F 6 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-26 | |
px.range52 | 52-week range | $121.57 – $170.46 | UNRECORDED | Stored company-profile observation — Captured 2026-10-25 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 37.97× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $7.69B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-26. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $4.74 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-26, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 3.14% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-21.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($14.41B) with the recorded estimate ($14.07B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-21.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($2.4100) with the recorded estimate ($2.1700) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 86 of 100 · Exceptional · pillars 94 / 46 / 54 / 90 / 75 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 86 (stored snapshot Oct 24, 2026) → 86 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-29.revenue_k,fin.q_table.depth.2025-09-29.rd_k,fin.q_table.depth.2025-09-29.sga_k,fin.q_table.depth.2025-09-29.operating_result_k. - Earnings-history note. Source series as of 2026-07-21. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-21.revenue_actual,earn.history.depth.2026-07-21.revenue_estimated,earn.history.depth.2026-07-21.revenue_actual.comparison,earn.history.depth.2026-07-21.eps_actual.comparison,earn.history.depth.2026-07-21.eps_actual,earn.history.depth.2026-07-21.eps_estimated,earn.history.depth.2026-04-28.revenue_actual,earn.history.depth.2026-04-28.revenue_estimated,earn.history.depth.2026-04-28.eps_actual,earn.history.depth.2026-04-28.eps_estimated,earn.history.depth.2026-02-04.revenue_actual,earn.history.depth.2026-02-04.revenue_estimated,earn.history.depth.2026-02-04.eps_actual,earn.history.depth.2026-02-04.eps_estimated,earn.history.depth.2025-10-28.revenue_actual,earn.history.depth.2025-10-28.revenue_estimated,earn.history.depth.2025-10-28.eps_actual,earn.history.depth.2025-10-28.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-29.operating_cash_flow_m,fin.opcf.depth.2025-09-29.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | NOVARTIS AG Our market-data provider lists the name as "Novartis AG"; the filer's own record is used here. | 2026-09-12 | OFFICIAL | SEC EDGAR filer record |
| Ticker / exchange | NVS on NYSE | 2026-09-12 | OFFICIAL | SEC EDGAR filer record |
| Business description | Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Top 20 products: $32.14B; Rest of portfolio: $9.16B; Total anti-infectives net sales: $1.20B; Anti Infectives sold under Sandoz name: $777.00M | 2022-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Headquarters | LICHTSTRASSE 35, BASEL, V8, CH 4056 Our market-data provider lists "Lichtstrasse 35, Basel, BS, 4056, CH"; the address on file with the SEC is used here. | 2026-09-12 | OFFICIAL | SEC EDGAR filer business address |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-21 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash, investments and debt | Total debt: $49.01B; Liquidity basis: cash and short-term investments; Total liabilities: $80.09B; Cash and short-term investments: $7.69B; Cash and investments: $10.06B; Long-term investments: $2.37B; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $10.06B; Cash and short-term investments: $7.69B; Long-term investments: $2.37B; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $7.69B; Decline: $6.33B; Opening balance: $14.02B; Average change per period: $904.30M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$41.32B; Total debt: $49.01B; Cash and investments: $7.69B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 0.67; Current ratio: 0.86; Debt to equity: 1.18; Net margin: 23.1%; Gross margin: 74.3%; Operating margin: 29.9%; Return on assets: 10.3%; Return on equity: 29.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-10-27; EPS estimate: $2.24 per share; Revenue estimate: $14.61B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.
ETFs that hold NVS
Funds in our ETF coverage that list NVS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.